Nurchis Mario Cesare, Raspolini Gian Marco, Derrico Pietro, Favaretti Carlo, Ritrovato Matteo, Nollo Giandomenico, Damiani Gianfranco
Department of Life Science, Health, and Health Professions, https://ror.org/035mh1293Università degli Studi Link, Rome, Italy.
Department of Health Science and Public Health, Section of Hygiene, https://ror.org/03h7r5v07Università Cattolica del Sacro Cuore, Rome, Italy.
Int J Technol Assess Health Care. 2025 Jul 8;41(1):e44. doi: 10.1017/S0266462325100251.
Health technology assessment of medical devices (HTA-MDs) presents unique challenges compared to pharmaceuticals. Total MD expenditure continues to grow in Europe, and countries typically conduct their own HTA-MDs evaluations, with varying institutionalization arrangements. European Union's (EU's) HTA Regulation aims to establish collaborative clinical assessments across Member States, potentially expediting the path from EU safety certification of MDs to pricing and reimbursement decisions. This study aims to identify emergent configurations among institutionalizations of HTA-MDs in the EU, European Economic Area (EEA), and European Free Trade Association (EFTA) countries.
Publicly available data were cross-sectionally collected for EU, EEA, and EFTA countries until August 2024 to allow a cross-country analysis of HTA-MDs institutionalizations. Countries were included if they had at least one publicly mandated body for HTA-MDs. Data sources were scientific databases, institutional websites, and HTA bodies' documentation. A framework of 16 elements, qualitatively describing the institutionalization of HTA-MDs, was developed based on a document review and used as a dataset for agglomerative hierarchical cluster analysis to identify patterns of HTA-MDs institutionalization.
The 21 included countries formed three clusters: Cluster 1 featured regulatory-focused, legally bound HTA-MDs systems with mandatory assessments determining reimbursement decisions; Cluster 2 was characterized by regulatory functions, external expert collaboration, formal prioritization processes, and organized Horizon Scanning; Cluster 3 showed recommendatory functions, nonmandatory assessments, and limited impact on reimbursement decisions.
HTA-MDs institutionalizations could benefit from implementing prioritization processes of evaluations, establishing networks of collaborative assessment centers, and ensuring links between evaluations and reimbursement decisions.
与药品相比,医疗器械的卫生技术评估(HTA-MDs)面临着独特的挑战。在欧洲,医疗器械的总支出持续增长,各国通常自行开展医疗器械卫生技术评估,其制度化安排各不相同。欧盟(EU)的卫生技术评估法规旨在在成员国之间建立协作性临床评估,这可能会加快医疗器械从欧盟安全认证到定价和报销决策的进程。本研究旨在确定欧盟、欧洲经济区(EEA)和欧洲自由贸易联盟(EFTA)国家医疗器械卫生技术评估制度化过程中出现的不同模式。
截至2024年8月,对欧盟、欧洲经济区和欧洲自由贸易联盟国家的公开数据进行横断面收集,以便对医疗器械卫生技术评估的制度化进行跨国分析。如果一个国家至少有一个公开授权的医疗器械卫生技术评估机构,则将其纳入研究。数据来源包括科学数据库、机构网站和卫生技术评估机构的文件。在文献综述的基础上,制定了一个包含16个要素的框架,用于定性描述医疗器械卫生技术评估的制度化,并将其用作凝聚层次聚类分析的数据集,以确定医疗器械卫生技术评估制度化的模式。
纳入研究的21个国家形成了三个集群:集群1的特点是专注于监管、具有法律约束力的医疗器械卫生技术评估系统,通过强制性评估来决定报销决策;集群2的特点是具有监管职能、外部专家合作、正式的优先级确定流程和有组织的前景扫描;集群3具有推荐功能、非强制性评估,对报销决策的影响有限。
医疗器械卫生技术评估的制度化可通过实施评估的优先级确定流程、建立协作评估中心网络以及确保评估与报销决策之间的联系而受益。